A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, open-label phase II clinical trial to evaluate alprostadil
liposomal injection in the prevention of contrast-induced acute kidney injury in patients
undergoing percutaneous coronary intervention.